Follow the Money to Medical Devices & Diagnostics
Spotlight on Lumicell, Inc.
Lumicell is a private US company that develops technologies that enable surgeons to see cancerous cells left behind before concluding surgical removal of a malignant tumor. It raised $28.7 million in the completion of a venture capital investment as reported in the PharmSource Lead Sheet on December 14, 2017.
- Lumicell was founded in 2008
- Corporate Headquarters: Wellesley, MA
- Lumicell plans to use the proceeds to support the clinical development of its LUM intra-operative image-guidance system:
Device: LUM Imaging SystemTM
Development Phase: Pilot studies
Medical Specialty: Oncology; Surgery
Purpose: Diagnostic – in vivo/Imaging devicel
Type: System/System accessory
Description: A lightweight handheld single-cell detection imaging device with a wide field of view and a cancer-specific molecular imaging agent. The system enables surgeons to detect residual cancer cells in real time within the tumor bed.
Medical Device & Diagnostics Pipeline1
|Product Candidate||Indication||Medical Specialty||Purpose||Type||Status|
|LUM Imaging System||Breast Cancer||Oncology; Surgery||Diagnostic – in vivo/Imaging device||System/System accessory||Pilot studies|
1Source: PharmSource Lead Sheet
|Lumicell, Inc.||Key Officers|
|80 William Street, Suite 260||Kelly Londy, CEO|
|Wellesley, MA 02481 USA||Jorge Ferrer, PhD, SVP, R&D|
|Web: http://lumicell.com/||Felix Geissler, CMO|
|Phone: +1-781-684-0218||David Strasfeld, PhD, Director, R&D|
Follow the Money to Pharmaceutical Opportunities – Spotlight on Fusion Pharmaceuticals, Inc.
Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ARMO BioSciences, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on CymaBay Therapeutics